Skip to main content

MDS

Criteria to qualify for study: Drug used in study:
  • MDS IPSS High-Risk or Intermediate 2
  • Intolerant of Hypomethylating Agents or not have responded to 4 cycles of decitabine or 6 cycles of azacidine
  • Progressed after initation of HMA

HEMREF 48 - H3B-8800-101 H3 Biomedicine and Eisai

HEMREF 48 - H3B-8800-101 H3 Biomedicine and Eisai

Criteria to qualify for study: Drug used in study:
  • Untreated
  • IPSS > 1.5
  • Untreated for MDS with the exception of transfusions, growth factors
  • WBC < 20,000, excluded if prior treatment with lenalidomide or HMAs

MDS 19 SGN33A-004 Seattle Genetics

A Phase 1/2 Study of Vadastuximab Talirine (SGN33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate -2 or High-Risk Myelodysplastic Syndrome (MDS)

ON HOLD